These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2174 related articles for article (PubMed ID: 26558876)
1. CTLA-4 and PD-1 Pathways: Similarities, Differences, and Implications of Their Inhibition. Buchbinder EI; Desai A Am J Clin Oncol; 2016 Feb; 39(1):98-106. PubMed ID: 26558876 [TBL] [Abstract][Full Text] [Related]
2. The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma. Mahoney KM; Freeman GJ; McDermott DF Clin Ther; 2015 Apr; 37(4):764-82. PubMed ID: 25823918 [TBL] [Abstract][Full Text] [Related]
3. PD-1 checkpoint blockade alone or combined PD-1 and CTLA-4 blockade as immunotherapy for lung cancer? Tanvetyanon T; Gray JE; Antonia SJ Expert Opin Biol Ther; 2017 Mar; 17(3):305-312. PubMed ID: 28064556 [TBL] [Abstract][Full Text] [Related]
4. Combination therapy with PD-1 or PD-L1 inhibitors for cancer. Hayashi H; Nakagawa K Int J Clin Oncol; 2020 May; 25(5):818-830. PubMed ID: 31549270 [TBL] [Abstract][Full Text] [Related]
6. Immune Checkpoint Inhibitors: New Insights and Current Place in Cancer Therapy. La-Beck NM; Jean GW; Huynh C; Alzghari SK; Lowe DB Pharmacotherapy; 2015 Oct; 35(10):963-76. PubMed ID: 26497482 [TBL] [Abstract][Full Text] [Related]
7. The emerging use of immune checkpoint blockade in the adjuvant setting for solid tumors: a review. Moujaess E; Haddad FG; Eid R; Kourie HR Immunotherapy; 2019 Nov; 11(16):1409-1422. PubMed ID: 31621445 [TBL] [Abstract][Full Text] [Related]
8. Targeting immune checkpoints in unresectable metastatic cutaneous melanoma: a systematic review and meta-analysis of anti-CTLA-4 and anti-PD-1 agents trials. Yun S; Vincelette ND; Green MR; Wahner Hendrickson AE; Abraham I Cancer Med; 2016 Jul; 5(7):1481-91. PubMed ID: 27167347 [TBL] [Abstract][Full Text] [Related]
9. [Drug therapy of melanoma: anti-CTLA-4 and anti-PD-1 antibodies]. Robert C; Mateus C Bull Acad Natl Med; 2014 Feb; 198(2):297-308. PubMed ID: 26263705 [TBL] [Abstract][Full Text] [Related]
12. Safety profiles of anti-CTLA-4 and anti-PD-1 antibodies alone and in combination. Boutros C; Tarhini A; Routier E; Lambotte O; Ladurie FL; Carbonnel F; Izzeddine H; Marabelle A; Champiat S; Berdelou A; Lanoy E; Texier M; Libenciuc C; Eggermont AM; Soria JC; Mateus C; Robert C Nat Rev Clin Oncol; 2016 Aug; 13(8):473-86. PubMed ID: 27141885 [TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of anti-PD-1 and anti-PD-1 combined with anti-CTLA-4 immunotherapy to advanced melanoma: A systematic review and meta-analysis of randomized controlled trials. Hao C; Tian J; Liu H; Li F; Niu H; Zhu B Medicine (Baltimore); 2017 Jun; 96(26):e7325. PubMed ID: 28658143 [TBL] [Abstract][Full Text] [Related]
14. Association of Anti-Programmed Cell Death 1 Antibody Treatment With Risk of Recurrence of Toxic Effects After Immune-Related Adverse Events of Ipilimumab in Patients With Metastatic Melanoma. Brunot A; Grob JJ; Jeudy G; Grange F; Guillot B; Kramkimel N; Mortier L; Le Corre Y; Aubin FF; Mansard S; Lebbé C; Blom A; Montaudie H; Giacchero D; Prey S; Legoupil D; Guyot A; Amini-Adle M; Granel-Brocard F; Meyer N; Dinulescu M; Edeline J; Campillo-Gimenez B; Lesimple T JAMA Dermatol; 2020 Sep; 156(9):982-986. PubMed ID: 32667663 [TBL] [Abstract][Full Text] [Related]
18. Distinct Immune Cell Populations Define Response to Anti-PD-1 Monotherapy and Anti-PD-1/Anti-CTLA-4 Combined Therapy. Gide TN; Quek C; Menzies AM; Tasker AT; Shang P; Holst J; Madore J; Lim SY; Velickovic R; Wongchenko M; Yan Y; Lo S; Carlino MS; Guminski A; Saw RPM; Pang A; McGuire HM; Palendira U; Thompson JF; Rizos H; Silva IPD; Batten M; Scolyer RA; Long GV; Wilmott JS Cancer Cell; 2019 Feb; 35(2):238-255.e6. PubMed ID: 30753825 [TBL] [Abstract][Full Text] [Related]
19. Nivolumab and pembrolizumab as immune-modulating monoclonal antibodies targeting the PD-1 receptor to treat melanoma. Faghfuri E; Faramarzi MA; Nikfar S; Abdollahi M Expert Rev Anticancer Ther; 2015; 15(9):981-93. PubMed ID: 26313415 [TBL] [Abstract][Full Text] [Related]
20. The Future of Immunotherapy in the Treatment of Small Cell Lung Cancer. Horn L; Reck M; Spigel DR Oncologist; 2016 Aug; 21(8):910-21. PubMed ID: 27354668 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]